SXTC
NASDAQ · Pharmaceuticals
China Sxt Pharmaceuticals In
$2.83
-0.10 (-3.41%)
Financial Highlights (FY 2026)
Revenue
1.17M
Net Income
-6,403,054
Gross Margin
21.8%
Profit Margin
-545.2%
Rev Growth
-16.7%
D/E Ratio
0.03
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 21.8% | 21.8% | 67.2% | 67.2% |
| Operating Margin | -625.9% | -563.3% | 22.1% | 21.0% |
| Profit Margin | -545.2% | -518.0% | 15.9% | 16.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.17M | 1.41M | 998.7K | 833.6K |
| Gross Profit | 256.6K | 308.1K | 670.8K | 559.9K |
| Operating Income | -7,350,364 | -7,943,476 | 220.6K | 175.0K |
| Net Income | -6,403,054 | -6,919,726 | 158.4K | 135.2K |
| Gross Margin | 21.8% | 21.8% | 67.2% | 67.2% |
| Operating Margin | -625.9% | -563.3% | 22.1% | 21.0% |
| Profit Margin | -545.2% | -518.0% | 15.9% | 16.2% |
| Rev Growth | -16.7% | -16.7% | +6.7% | -0.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 32.3K | 32.3K | 1.27M | 1.32M |
| Total Equity | 960.1K | 960.1K | 1.77M | 1.97M |
| D/E Ratio | 0.03 | 0.03 | 0.71 | 0.67 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -7,280,215 | -8,304,760 | 317.7K | 242.4K |
| Free Cash Flow | — | — | 143.5K | 109.6K |